International Journal of Radiation Oncology*Biology*Physics 2013-11-15

Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplant

Ji Hyun Kim, Anthony Stein, Nicole Tsai, Timothy E. Schultheiss, Joycelynne Palmer, An Liu, Joseph Rosenthal, Stephen J. Forman, Jeffrey Y.C. Wong

Index: Int. J. Radiat. Oncol. Biol. Phys. 89(1) , 75-81, (2014)

Full Text: HTML

Abstract

Purpose Approximately 5-20% of patients can develop extramedullary (EM) relapse after total body irradiation (TBI) containing hematopoietic cell transplant (HCT). While total marrow and lymphoid irradiation (TMLI) provides a more conformally targeted radiotherapy for patients, organ sparing has the potential to place the patient at a higher risk for EM relapse compared to TBI. This study evaluates EM relapse in patients treated with TMLI at our institution.

Related Compounds

  • Etoposide
  • Busulfan
  • Fludarabine
  • melphalan
  • Vidarabine

Related Articles:

TAp73 promotes cell survival upon genotoxic stress by inhibiting p53 activity.

2014-09-30

[Oncotarget 5(18) , 8107-22, (2014)]

DNA damage-specific deubiquitination regulates Rad18 functions to suppress mutagenesis.

2014-07-21

[J. Cell Biol. 206(2) , 183-97, (2014)]

SK053 triggers tumor cells apoptosis by oxidative stress-mediated endoplasmic reticulum stress.

2015-02-15

[Biochem. Pharmacol. 93(4) , 418-27, (2015)]

ELF-MF attenuates quercetin-induced apoptosis in K562 cells through modulating the expression of Bcl-2 family proteins.

2014-12-01

[Mol. Cell Biochem. 397(1-2) , 33-43, (2014)]

High-throughput screening identifies inhibitors of DUX4-induced myoblast toxicity.

2014-01-01

[Skelet. Muscle 4 , 4, (2014)]

More Articles...